Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
23andMe Holding Comp (ME)
3.01 ? -0.09 (-2.90%)
Volume: 1,841,915 @04/29/22 7:55:36 PM EDT
Bid Ask Day's Range
3.01 3.1 2.97 - 3.21
ME Detailed Quote
23andMe Holding Comp (ME)
3.7 ? -0.47 (-11.27%)
Volume: 6,508,932 @03/11/22 7:59:07 PM EST
Bid Ask Day's Range
3.69 3.71 3.58 - 4.255
ME Detailed Quote
23andMe Holding Comp (ME)
4.72 ? 0.19 (4.19%)
Volume: 2,098,817 @02/04/22 7:56:56 PM EST
Bid Ask Day's Range
4.52 4.78 4.47 - 4.83
ME Detailed Quote
Thought this was a good company lol below 5??
$50M further commitment from GSK, and stock is down today. Market has no clue what's coming.
23andMe Announces Extension of GSK Collaboration and Update on Joint Immuno-oncology Program
http://crweworld.com/article/news-provided-by-globenewswire/2259227/23andme-announces-extension-of-gsk-collaboration-and-update-on-joint-immuno-oncology-program
$ME going to be one of the largest growth stocks of the next decade?
jimmy you buying these 7.50's??
23andMe Holding Comp (ME)
13.1 ? 0.23 (1.79%)
Volume: 3,057,788 @11/05/21 7:44:46 PM EDT
Bid Ask Day's Range
13.1 13.2 12.6 - 13.34
ME Detailed Quote
Quiet board! Shorts upped there position from 12% to 19% of float yesterday, with 3m shares borrowed.
finally got some reads $ME
23andMe Holding Co. NASDAQ: ME
ME
GoSymbol lookup
Health Care : Life Sciences Tools & Services | Company profile
23andMe Holding Co., formerly VG Acquisition Corp., is a consumer
genetics and research company.
The Company offers direct-to-consumer genetic testing and
personalized information about genetic health risks, ancestry,
and traits. The Company operates through two segments:
Consumer & Research Services and Therapeutics.
Its consumer & research services business segment comprises personal genome service (PGS) and research services.
Its PGS provides a suite of genetic reports,
including information on genetic ancestral origins,
personal genetic health risks, rare carrier conditions to their children, as well as reports on how genetics can impact responses
to medications.
The Company’s therapeutics segment focuses on drug development
for discovering and developing therapies to improve patient lives
and includes out-licensing of intellectual property.
The Company’s programs across therapeutic areas, include oncology, immunology, neurology, metabolic and cardiovascular diseases.
$ME 52-Wk Range 7.01 - 18.16 Low High
HERE ME
23andMe Holding Co.
https://www.otcmarkets.com/stock/ME/quote
SO NAME IS 23ANDME ?????
WHAT IS NAME & SYMBOL PLEASE ?????
VG Acquisition Corp (VGAC)
10.99 ? 0.0 (0.00%)
Volume: 0 @-
Bid Ask Day's Range
- - - - -
VGAC Detailed Quote
Is this board ever going to change to ME?
VG Acquisition Corp (VGAC)
10.99 ? 0.0 (0.00%)
Volume: 0 @-
Bid Ask Day's Range
- - - - -
VGAC Detailed Quote
VG Acquisition Corp (VGAC)
10.99 ? 0.0 (0.00%)
Volume: 0 @-
Bid Ask Day's Range
- - - - -
VGAC Detailed Quote
23andMe rises after Richard Branson SPAC merger
- 23andMe, the genetic testing company that pioneered the business of personalized gene testing kits, traded higher in its public market debut under the ticker symbol “ME” on Thursday after a merger with a Richard Branson SPAC.
- 23andMe founder and CEO Anne Wojcicki told CNBC the company is planning to build a big consumer business off its base of 11 million customers and drug research and development platform with near-80% of test takers opting into sharing their genetic information for disease R&D.
- It is a five-time CNBC Disruptor 50 company.
https://www.cnbc.com/2021/06/17/gene-testing-firm-23andme-trades-higher-after-branson-spac-merger-.html
Is this boards name going to change to ME?
Enormous growth potential, 40+ pipeline, Ticker change to ME yesterday.
Trading is expected to begin on Nasdaq on June 17, 2021, under the new ticker symbol "ME" for the New 23andMe Class A common stock and "MEUSW" for the New 23andMe warrants.
YES I AGREE VG Acquisition Corp (VGAC)
11.1 ? 0.93 (9.14%)
Volume: 6,054,642 @06/10/21 4:19:46 PM EDT
Bid Ask Day's Range
- - 10.22 - 11.25
VGAC Detailed Quote
Nice day today VGAC
VG Acquisition Corp (VGAC)
9.97 ? 0.0 (0.00%)
Volume: 457,368 @05/26/21 11:56:22 AM EDT
Bid Ask Day's Range
- - 9.96 - 9.99
VGAC Detailed Quote
thank you, most spac's trading in is area pps VG Acquisition Corp (VGAC)'
thank you, most spac's trading in is area pps VG Acquisition Corp (VGAC)'
Bought some today at 10.015
VG Acquisition Corp (VGAC)
9.97 ? -0.04 (-0.40%)
Volume: 1,413,864 @04/16/21 7:55:26 PM EDT
Bid Ask Day's Range
- - 9.96 - 10.0101
VGAC Detailed Quote
Bought a bunch @ 11 and will be buying more if it dips. Looks like a great entry price for a solid company.
I'm adding quietly in these low 11s and 10s if I can
Give it time. This one has long legs and none of the black clouds.
Another great call Bear.
Welcome aboard Tommy.
Most are not understanding the value in the genetic database/therapeutic potential IMO. Definitely a long play/investment.
SPAC's being beat up badly. Can VGAC emerge from the pack?
With Cciv and this spac no one will buy another until after it has closed and started again as another ticker
VG Acquisition Corp (VGAC)
13.09 ? -0.28 (-2.09%)
Volume: 2,572,492 @02/19/21 7:59:11 PM EST
Bid Ask Day's Range
- - 12.95 - 13.49
VGAC Detailed Quote
Added a few hundred shares.. exciting times ahead in the future of drug development.
Took a starter position Friday before the close. Bought several 23andMe kits for the family during the holidays. Even purchased the result books. Great gift, very informative, terrific service. GLTA
DNA databank
Partnerships with Glakso Smith Kline for drug development and investments from Genentech.
I, for some reason, keep thinking about future vaccines...
Followers
|
19
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
170
|
Created
|
11/30/20
|
Type
|
Free
|
Moderators |
Most people know 23andMe (NASDAQ:ME) for its consumer-facing genetics testing kits,
and while this is certainly an excellent revenue stream, it's not the most exciting part of the company's business.
Where the real long-term potential lies is in the massive genetics data library the company has accumulated, with nearly 12 million genotyped individuals.
To put this in context, consider that the second-largest collection of genetic data belongs to Regeneron Pharmaceuticals, which has less than 10% of this amount.
Here's the point. 23andMe has a 50-50 partnership with pharmaceutical giant GlaxoSmithKline to leverage the company's genetics information to develop therapeutics.
The company currently has some exciting candidates, and if successful,
this could easily be a multibillion-dollar revenue stream for 23andme, which is currently valued at just $3.3 billion.
65 Bleecker Street
6th Floor
New York, NY 10012
FORM TYPE | RECEIVED | PERIOD END DATE | REPORT |
---|---|---|---|
4 | 12/10/2020 | 09/24/2020 | PDFRTFHTMLXLS |
4 | 12/10/2020 | 09/24/2020 | PDFRTFHTMLXLS |
4 | 12/10/2020 | 09/24/2020 | PDFRTFHTMLXLS |
4 | 12/10/2020 | 12/08/2020 | PDFRTFHTMLXLS |
4/A | 12/10/2020 | 09/24/2020 | PDFRTFHTMLXLS |
4 | 12/10/2020 | 09/24/2020 | PDFRTFHTMLXLS |
8-K | 11/20/2020 | 11/20/2020 | PDFRTFHTMLXLS |
10-Q | 11/16/2020 | 09/30/2020 | PDFRTFHTMLXLS |
8-K | 10/22/2020 | 10/16/2020 | PDFRTFHTMLXLS |
8-K | 10/13/2020 | 10/06/2020 | PDFRTFHTMLXLS |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |